Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics (Q37608910)

21 August 2017

1 reference

title

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics (English)

1 reference

21 August 2017

0 references

1

Ayalew Tefferi

1 reference

21 August 2017

3

James W Vardiman

1 reference

21 August 2017

Radek Skoda

2

1 reference

PubMed ID

19806146

21 August 2017

language of work or name

English

0 references

publication date

6 October 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

11

1 reference

21 August 2017

627-637

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

The genetic basis of myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Mutation in TET2 in myeloid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Mast cells and mastocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Hematopathologic findings in chronic idiopathic myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Can morphological assessment limit the use of specific genetic testing to exclude chronic myeloid leukaemia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Conventional cytogenetics in myelofibrosis: literature review and discussion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Structural organization of the bcr gene and its role in the Ph' translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A gain-of-function mutation of JAK2 in myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

The complete evaluation of erythrocytosis: congenital and acquired

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Eosinophilia: secondary, clonal and idiopathic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.149

Some speculations on the myeloproliferative syndromes.

31 March 2020

1 reference

12 December 2020

Chromosome studies on normal and leukemic human leukocytes

1 reference

12 December 2020

Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis

1 reference

12 December 2020

BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: clinical presentation.

1 reference

12 December 2020

10.1038/NRCLINONC.2009.149

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19806146